Build confidence in every regulated decision.
GlobalNEP helps life sciences organizations ensure that data is complete, consistent, accurate, attributable, and available throughout its lifecycle - across paper, hybrid, and electronic environments.
Data integrity is an organizational system
Reliable data depends on more than system configuration. Governance, process design, human behavior, access, review, interfaces, audit trails, records management, and management oversight must work together. We use a risk-based approach to identify where a failure could affect product quality, patient safety, regulatory decisions, or the ability to reconstruct what occurred.
How we help
Program and governance assessment
Evaluate policy, ownership, oversight, metrics, escalation, training, and the integration of data integrity into the quality system.
Data-flow and lifecycle mapping
Trace how data is created, processed, reviewed, transferred, reported, retained, archived, and retrieved.
Process and system risk assessment
Prioritize vulnerabilities across laboratories, manufacturing, quality, engineering, automation, and business processes.
Control evaluation
Assess roles and access, metadata, audit trails, review practices, interfaces, manual transcription, backup, archival, and record reconstruction.
Remediation strategy
Develop risk-ranked actions that address immediate exposure, underlying causes, systemic weaknesses, and effectiveness monitoring.
Culture and capability
Strengthen expectations, decision-making, speak-up behaviors, investigation quality, and management accountability.
Our approach
• Start with data use and criticality, not only the application inventory.
• Evaluate the full lifecycle, including people, process, technology, and governance.
• Address immediate risk while correcting systemic causes.
• Monitor control effectiveness and emerging vulnerabilities over time.
What clients gain
• Greater confidence in the reliability and traceability of regulated data
• Visibility into high-risk data flows and control gaps
• Remediation priorities tied to patient, product, and compliance impact
• Clearer governance across quality, business, and technology owners
• Sustainable monitoring instead of one-time correction
Designed for a regulated environment
The approach reflects FDA's expectation that CGMP data be reliable and accurate and that firms use meaningful, risk-based strategies informed by process understanding and technology.